戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ients, increased 18F-FDG uptake identified a second primary malignancy.
2 stence or recurrence, distant metastases, or second primary malignancy.
3 ears of follow-up and to explore the risk of second primary malignancies.
4 r surveillance to promote early detection of second primary malignancies.
5  survivors have an increased risk of various second primary malignancies.
6       Twenty-two patients (2.7%) developed a second primary malignancy, 13 (3.2%) and 9 (2.2%) in the
7        We investigated the long-term risk of second primary malignancy after chemotherapy for Hodgkin
8                                              Second primary malignancies and premature death are a co
9  associated with a small increase in risk of second primary malignancies and with increased risk of p
10 ce of all second primary malignancies, solid second primary malignancies, and haematological second p
11 ond primary malignancies, and haematological second primary malignancies, and were analysed by a one-
12                 Cumulative incidences of all second primary malignancies at 5 years were 6.9% (95% CI
13                  The cumulative incidence of second primary malignancies at 60 months after trial ent
14           The cumulative incidence rate of a second primary malignancy before disease progression was
15  follow-up, there is no difference regarding second primary malignancies between groups.
16 second primary malignancy diagnosis, type of second primary malignancy, date of death or last contact
17 ce treatment, date of first relapse, date of second primary malignancy diagnosis, type of second prim
18  increased risk of developing haematological second primary malignancies, driven mainly by treatment
19                                              Second primary malignancies excluding nonmelanoma skin c
20       There is no emerging safety signal for second primary malignancies following VMP.
21 sion and overall survival and an increase in second primary malignancies for lenalidomide at a median
22                                        Three second primary malignancies have been reported.
23 ene may be associated with increased risk of second primary malignancies in glioma patients.
24              Lenalidomide has been linked to second primary malignancies in myeloma.
25 dicating premalignant lesions and preventing second primary malignancies in patients cured of squamou
26 smani et al provide important information on second primary malignancies in patients treated with tha
27 e available data to compare the incidence of second primary malignancies in patients with and without
28 an increased awareness of the possibility of second primary malignancies in patients with thymoma.
29   Three haematological and five solid tumour second primary malignancies in the placebo group were in
30 %) haematological and nine (4%) solid tumour second primary malignancies in the placebo group.
31 ficantly associated with the occurrence of a second primary malignancy in the same patient.
32                           Follow-up-adjusted second primary malignancies incidence rates were 2.3 and
33 ncrease in haematological adverse events and second primary malignancies, lenalidomide maintenance th
34 l cancer (n = 7), lack of follow-up (n = 4), second primary malignancy (n = 3), or chemotherapy befor
35                                           No second primary malignancies occurred, and no patient req
36 nfections (OR, 2.03 [95% CI, 1.41 to 2.92]), second primary malignancies (OR, 1.77 [95% CI, 0.89 to 3
37 m randomisation to breast cancer recurrence, second primary malignancy, or death, and was analysed by
38 halan significantly increased haematological second primary malignancy risk versus melphalan alone (H
39 24]; p=0.76) did not increase haematological second primary malignancy risk versus melphalan alone.
40 of interest were cumulative incidence of all second primary malignancies, solid second primary malign
41 fied an association between lenalidomide and second primary malignancies (SPM) in patients with multi
42                                              Second primary malignancies (SPM) were observed in 8 pat
43 ll carcinoma (HNSCC) are at elevated risk of second primary malignancies (SPM), most commonly of the
44 ssociated with increased risks of developing second primary malignancies (SPM).
45 though studies have investigated the risk of second primary malignancies (SPMs) associated with lymph
46 e rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3.62.
47            Evaluation for the development of second primary malignancies (SPMs) was conducted, and no
48 apy is associated with a higher incidence of second primary malignancies (SPMs), including both hemat
49 nd the relative risks of developing distinct second primary malignancies (SPMs).
50              Standardised incidence ratio of second primary malignancies was 3.1 (95% CI 1.7-5.0) in
51 I 0.62-2.00]; p=0.72), and of haematological second primary malignancies were 3.1% (95% CI 1.9-4.3) a
52        Cumulative 5-year incidences of solid second primary malignancies were 3.8% (95% CI 2.7-4.9) i
53                                      Data on second primary malignancies were collected by individual
54 (8%) haematological and 14 (6%) solid tumour second primary malignancies were diagnosed after randomi
55                                           15 second primary malignancies were reported in 12 patients
56                                              Second primary malignancies were reported in 4%, includi
57                                              Second primary malignancies were reported in 536 of 12 3
58         Toxicity profiles and development of second primary malignancies were similar across treatmen
59             Standardised incidence ratios of second primary malignancies were similar between the ABV
60                  Eight patients developed 11 second primary malignancies with an excess frequency of